The Australian Government’s new process to consider complaints about the advertising of medicines and medical devices to the public is being backed by the Australian Dental Industry Association.
Through the proposed 2018 Therapeutic Goods Advertising Code the Australian Government has set out a revised framework for the advertising of medicines and medical devices.
This Code seeks to promote the safe and effective use of therapeutic goods and works to ensure that advertising of medicines and medical devices to the public is ethical and does not mislead or deceive the consumer or create unrealistic expectations. The supporting complaints handling process is currently being developed by the Therapeutic Goods Administration.
ADIA has welcomed the Australian Government’s decision to make the TGA the single body responsible for the handling of complaints about the advertising of therapeutic goods to the public.
“This is a significant simplification of the previous system where multiple bodies considered complaints,” ADIA CEO Troy Williams said.
“The new arrangements will make it easier for the dental industry to comply with the Code and respond to any complaints.”
ADIA’s advice to the TGA was that the dental industry was supportive of the proposed graduated complaint handling model. This sees the regulator take action against businesses that have been found to have breached the code in a manner proportionate to the risk posed to the public.
The model proposed by the TGA is consistent with a risk-based approach to regulation and will enable it to enforce the Code without subjecting businesses to onerous requirements. It’s therefore supported by ADIA.
“In providing our support, ADIA emphasised the need for the TGA to take into account the challenges faced by small businesses,” Williams said. “These challenges should be a determining factor when the TGA considers regulatory actions in response to breaches of the Code.”
Based on a media release sourced from the ADIA website.